Welcoming the participants to the event, Suresh Kumar, President of Vimta Labs said, “The last decade has seen a substantial shift in the focus of pharma industry from small molecules to large molecules. Biologics is changing the way doctors treat diseases and health conditions that have eluded us over the years & are now helping us improve the Quality of Life. This change is more pronounced in the case of cancer, autoimmune and infectious diseases.”

He also announced that, “With the increasing emphasis on large molecule drugs, we have established a dedicated state-of-the-art facility for biologics development.We are proud to announce that Vimta has set up a Centre of Excellence for Bioassays.”

Contract Research and Testing Organization, Vimta Labs recently conducted Confluence - 2020, a knowledge sharing session to sensitize pharma industry about upcoming regulatory and scientific developments.The theme of the event was on development of large molecule drugs also called as biologics. Scientists and researchers from various parts of the globe interacted with the participants about the developments in their respective areas of research at this event.